NewsSan Diego Business JournalSeptember 14, 2026San Diego County
858 Therapeutics studies potential breast and ovarian cancer treatments
Photo: San Diego Business Journal
Clinical-stage drug developer 858 Therapeutics is advancing clinical studies for its lead drug candidate, ETX-19477, targeting breast and ovarian cancer subtypes in patients with BRCA gene mutations.
Read the full story at San Diego Business JournalWhy It Matters
Patients with specific BRCA gene mutations who have breast or ovarian cancer are the focus of ongoing clinical research into a new potential treatment option.
Key Facts
- 858 Therapeutics is a clinical-stage drug developer located in San Diego.
- The company's lead drug candidate is named ETX-19477.
- ETX-19477 is currently being studied for its efficacy in breast and ovarian cancer patients.
- The targeted patient group has mutations of the BRCA genes, which normally repair damaged DNA molecules.
Who's Mentioned
Organization858 Therapeutics“Clinical-stage drug developer studying ETX-19477.”locationSAN DIEGO“Location of the company”OrganizationGenentech“Company that acquired Jecure Therapeutics.”OrganizationU.S. Food and Drug Administration“Granted Fast Track designations to 858 Therapeutics.”OrganizationJecure Therapeutics“Former company led by Jeff Stafford.”otherETX-19477“Lead drug candidate being studied for breast and ovarian cancers.”PersonJeff Stafford“CEO of 858 Therapeutics.”OrganizationAmerican Society of Clinical Oncology“Conference where initial Phase 1/2 clinical data was presented.”locationSan Diego“Headquarters of 858 Therapeutics.”